The primary therapeutic indication for Eleanor 150/30 ED is the prevention of pregnancy in women of reproductive age. This use generally helps the cycle become more predictable and supports management of reproductive planning. The medication is also applied across domains where additional symptomatic support is needed.

Brief Listing of Indications: It is commonly used to help manage severe menstrual cramping (dysmenorrhea), abnormally heavy menstrual bleeding (menorrhagia), and irregular menstruation. It also supports the management of hormone-related skin manifestations, such as acne, and is associated with supportive benefit in the context of reproductive health.

“This support contributes to easing the overall symptom load, which supports general well-being during symptomatic phases.”

Management of Severe Menstrual Symptom Burdens

The medication is considered relevant for symptom-driven clinical presentations of conditions like endometriosis, is relevant for easing cyclic pelvic pain, as well as irregular menstruation. This provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

Quick Fact: Support for Menstrual Symptoms

Eleanor 150/30 ED supports the patient during difficult episodes by easing discomfort associated with heavy and painful periods, assisting with maintaining functional stability.

Eleanor 150/30 ED is officially approved for use by females of reproductive potential who have begun menstruation and who are not subject to any contraindications. Use is not indicated for pre-menarcheal girls or post-menopausal women.

Contraindicated Populations (Must Not Use)

Official regulatory documents define absolute contraindications for use of this combined hormonal contraceptive, primarily related to risk of severe cardiovascular events and hormone-sensitive conditions. The medicine is contraindicated for the following populations:

• Females over 35 years of age who smoke.
• Those with a current or history of arterial or venous thrombotic diseases, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or heart attack.
• Females with uncontrolled high blood pressure or hypertension with vascular disease.
• Those with severe liver disease (including tumors) or known/suspected hormone-sensitive malignancies (e.g., breast cancer).
• Females with migraine headaches with focal neurological symptoms (aura), or any migraine in women over 35.

Eligibility-Related Restrictions

Classification	Status/Restriction
Pregnancy	Contraindicated (Must be discontinued if pregnancy occurs).
Lactation/Breastfeeding	Not recommended (May decrease milk production).
Postpartum	Start no earlier than 4 weeks after delivery in non-breastfeeding females.
Major Surgery	Must be stopped at least 4 weeks before and 2 weeks after surgery or prolonged immobilization.

Official Interaction Restrictions and Prohibitions

Co-administration is formally contraindicated with specific antiviral treatments for chronic Hepatitis C. This includes medicinal products containing ombitasvir/paritaprevir/ritonavir, dasabuvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir. This prohibition is due to the documented risk of severe liver enzyme elevations, which is a required consideration of the regulatory profile.

Exposure Modification by Enzyme Modulators

The contraceptive hormones interact with substances that modulate liver enzymes. Co-administration with hepatic enzyme inducers (such as certain anticonvulsants and anti-tuberculosis medicines like Rifampicin) significantly reduces the plasma concentration and overall exposure of both Ethinylestradiol and Levonorgestrel. This reduction is associated with a loss of contraceptive effectiveness, requiring procedural constraints in use. Conversely, specific CYP3A4 inhibitors may increase the exposure of Ethinylestradiol. The official profile also identifies potential pharmacodynamic antagonism with certain Antithrombin agents.

Timing-Based and Food Interactions

A timing-based constraint applies to instances of gastrointestinal absorption interference. If vomiting or severe diarrhea occurs within four hours of tablet intake, the regulatory procedure mandates the use of an additional non-hormonal contraceptive method for a specified duration. The product’s profile also notes that consumption of Grapefruit Juice may be associated with increased Ethinylestradiol plasma concentrations.

How Eleanor 150/30 ED Works: Mechanism of Action

Central Suppression of Ovulation

Eleanor 150/30 ED delivers synthetic estrogen and progestin, which act on steroid hormone receptors within the hypothalamus and pituitary gland. This engagement initiates a negative feedback cascade that modulates the hypothalamic-pituitary-ovarian (HPO) axis, suppressing the release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This suppression results in the inhibition of follicular development and the subsequent release of an ovum (ovulation).

Alteration of Cervical and Endometrial Environment

The progestin component also modulates peripheral processes by engaging receptors in the lower reproductive tract. This causes the cervical mucus to increase in viscosity and become less permeable, a condition that resists sperm migration. Concurrently, the hormonal action induces structural and biochemical changes in the endometrium (uterine lining), establishing an environment that is less favorable for blastocyst nidation.

Instruction Map: How to use Eleanor 150/30 ED — Official Administration Guidelines

This map details the usage parameters for the combined oral contraceptive tablet, Eleanor 150/30 ED (Levonorgestrel 150 μg / Ethinylestradiol 30 μg).

---

Administration Scope

Instruction	Detail
Route of administration	Oral
Dosing schedule	One tablet daily, containing Levonorgestrel 150 μg and Ethinylestradiol 30 μg. The regimen consists of 21 active tablets followed by 7 inactive tablets in a 28-day cycle.
Timing in relation to meals (if applicable)	May be taken with or without food.
Preparation requirements (if applicable)	The tablet must be swallowed whole with water. No reconstitution or crushing is required.
Age-group administration rules	Not indicated for use in females who have not yet reached menarche.
Missed-dose rules	If a single active tablet is missed by less than 12 hours, instructions advise immediate ingestion. Longer delays or multiple missed tablets require following specific guidelines based on the week of the cycle.
Special procedural conditions	The tablet must be taken at approximately the same time every day. Tablets must be ingested in the specific order directed by the 28-day blister pack.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Daily, continuous (following a cyclic pattern)
Basis	Governed by prescribing information.
Use-context constraints	Requires strict adherence to fixed daily timing and the tablet sequence.

---

Resulting Procedural Structure

Official step sequence:

• Initiate the regimen using either a Day 1 Start or a Sunday Start method, as defined in prescribing information.
• Ingest one tablet orally, at the same time every day, following the blister pack sequence.
• Continue taking one tablet daily for the full 28-day cycle, including the inactive tablets.
• Immediately start a new 28-day blister pack on the day after the last tablet of the previous pack, ensuring continuous cyclic use.

Connection to the overall use protocol (2–4 sentences): The instructions establish a highly structured, time-sensitive protocol based on a continuous 28-day cycle of daily oral administration. This protocol dictates the sequential order and consistent daily timing of tablet ingestion, following the precise pattern documented in labeling. The core procedural structure requires the user to maintain an unbroken sequence of cycles by immediately starting a new pack.

Evidence for Use in Preventing Pregnancy

Research evaluating this medicine for preventing pregnancy relies on pivotal Randomized Controlled Trials (RCTs) and extensive large-scale observational cohorts. These studies monitor women of reproductive age, quantifying the rate of unintended pregnancy using the Pearl Index over defined periods. Regulatory reviews describe findings from trials reporting specific rates of use-related discontinuation. Studies report that overall measured outcomes are influenced by factors like the degree of adherence in real-world use.

---

Evidence for Secondary Uses in Research on Symptom Outcomes

Research has examined this medicine in contexts exploring how symptoms evolve over time, such as those related to menstruation. Randomized, placebo-controlled trials evaluated outcomes related to physical discomfort (dysmenorrhea) and measures related to systemic imbalance (menorrhagia). Researchers reported describing patterns related to pain severity scores and measured changes in menstrual blood loss. Studies also monitored patterns related to measured cycle regularity in the cohorts.

Research on Hormone-related Skin Conditions (Acne)

Dermatological outcomes were examined as a secondary focus. Trials monitored changes in lesion counts and evaluated overall changes using Global Acne Severity Scales. Study documentation notes that the evidence for acne was collected as a secondary focus compared to the primary indication.

---

Research Gaps and Areas of Uncertainty

Research highlights that long-term effects are not fully established regarding symptom control after stopping the medicine. The subjective nature of pain and bleeding severity measures means the evidence quality varies across trials. Data for certain groups, such as women with a high body mass index (BMI), remain insufficient, and comparative evidence is lacking for some secondary uses. Overall, research provides context but does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Common questions about Eleanor 150/30 ED (FAQ)

Q: Can I take this medication if I am pregnant?

Official regulatory documents indicate that there are no sufficient and well-controlled studies on this medicine's use in pregnant women. Based on non-human data, there is a potential for this medication to cause harm to a developing fetus.

Information regarding the medication's effects during pregnancy is collected through a pregnancy exposure registry.

---

Q: Does this medicine make you sleepy or drowsy?

Yes, official product information explicitly lists somnolence (drowsiness), sedation, and dizziness among the possible side effects. Due to these potential effects, official information includes warnings about performing activities that require mental alertness, such as driving or operating heavy machinery.

---

Q: Is it safe to use this medication long-term?

Official drug labels contain important safety warnings related to how the medication is used over time. This includes the potential for suicidal thoughts or behavior, which can begin early in treatment and may continue as long as the medicine is being taken. Regulatory warnings mention that using the medication, especially with other Central Nervous System depressants, carries a risk of serious breathing problems (respiratory depression).

---

Q: Can children 2 years old use this medicine?

Regulatory information specifies that this medication is indicated for use as an add-on treatment for partial onset seizures in pediatric patients starting at 3 years of age.

Safety and effectiveness of this medicine have not been established or studied in children younger than 3 years old.

How to Store and Dispose of Eleanor 150/30 ED?

This section outlines the official, mandatory storage and disposal rules for the oral contraceptive, based on regulatory labeling and government sources.

---

️ Storage and Packaging Requirements

• Temperature and Environment: The medicine must be stored below 25 C in a cool dry place and protected from excessive heat and freezing.
• Container Integrity: Keep the tablets in their original blister pack and outer carton to maintain product stability and protect them from light and moisture.
• Child Safety: It is a mandatory requirement to store the product out of the reach of children in a safe and secure location.

---

️ Disposal Instructions

• Expired Product: Do not take the medicine after the expiry date printed on the pack. Any expired or unused tablets must be returned to a pharmacist for disposal.
• Environmental Protection: The product must not be flushed down the toilet or drain, as required by environmental regulatory guidelines for safe medication disposal.